Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age

BACKGROUND: The safety, reactogenicity, immunogenicity, and efficacy of the mRNA-1273 coronavirus disease 2019 (Covid-19) vaccine in young children are unknown. METHODS: Part 1 of this ongoing phase 2–3 trial was open label for dose selection; part 2 was an observer-blinded, placebo-controlled evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Evan J., Creech, C. Buddy, Berthaud, Vladimir, Piramzadian, Arin, Johnson, Kimball A., Zervos, Marcus, Garner, Fredric, Griffin, Carl, Palanpurwala, Khozema, Turner, Mark, Gerber, Jeffrey, Bennett, Richard L., Ali, Kashif, Ampajwala, Madhavi, Berman, Gary, Nayak, Jennifer, Chronis, Carey, Rizzardi, Barbara, Muller, William J., Smith, Christopher A., Fuchs, George, Hsia, Daniel, Tomassini, Joanne E., DeLucia, Dianne, Reuter, Caroline, Kuter, Barbara, Zhao, Xiaoping, Deng, Weiping, Zhou, Honghong, Ramirez Schrempp, Daniela, Hautzinger, Kelly, Girard, Bethany, Slobod, Karen, McPhee, Roderick, Pajon, Rolando, Aunins, Anne, Das, Rituparna, Miller, Jacqueline M., Schnyder Ghamloush, Sabine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Massachusetts Medical Society 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634866/
https://www.ncbi.nlm.nih.gov/pubmed/36260859
http://dx.doi.org/10.1056/NEJMoa2209367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634866/
https://www.ncbi.nlm.nih.gov/pubmed/36260859
http://dx.doi.org/10.1056/NEJMoa2209367

Ejemplares similares